Historically, European governments, driven by global treaties like the 1961 Single Convention on Narcotic Drugs, categorised cannabis as a dangerous drug, to be outlawed and policed. As in much of the world, consumption of cannabis in Europe was mostly associated with counterculture movements in the 1960s and 1970s. Many European countries adopted a zero-tolerance approach, with hefty penalties for possession, distribution, or cultivation.
The hard-line stance began to soften in the 1990s, particularly in countries like the Netherlands. The famous Dutch coffee shop culture, which allows the sale of small amounts of cannabis in licensed establishments, was a pragmatic response to the failure of punitive measures. The Dutch approach offered a regulated alternative to black market drug trade, keeping it out of sight but not out of reach. However, full legalisation remained a distant dream.
By the turn of the 21st century, the conversation surrounding cannabis shifted dramatically. Increasingly, European citizens and policymakers began viewing cannabis not simply as an illegal drug, but as a substance with potential medical, recreational, and economic value. Across Europe, discussions about cannabis moved from hushed tones to public debate, buoyed by global trends toward decriminalisation.
The rise of medical cannabis spearheaded this transformation. In the early 2000s, countries like the United Kingdom, Germany, and Italy began allowing the use of cannabis for medical purposes under strict regulations. This move was driven by the growing body of scientific evidence supporting the medicinal benefits of cannabis in treating conditions such as epilepsy, chronic pain, and multiple sclerosis. The shift to medical legalisation underscored a broader cultural change: cannabis was no longer perceived as purely harmful but recognised for its therapeutic potential.
Full Legalisation: Small Steps, Big Implications
While medical cannabis found a relatively swift path to acceptance, full recreational legalisation has moved at a slower pace across the continent. Nonetheless, recent years have seen some groundbreaking changes. Luxembourg became the first European country to announce full legalisation for recreational use in 2018, with plans to allow home cultivation and the creation of a legal market. Malta followed in 2021, becoming the first EU member state to fully legalise the possession and cultivation of cannabis for personal use.
Germany, a critical player in the European Union, has also set the stage for full legalisation. In 2022, the German government outlined its plan to regulate the production and sale of recreational cannabis, potentially creating the largest regulated cannabis market in Europe. The move was driven in part by the realisation that criminalising cannabis use was not preventing consumption, but rather fuelling an illegal market that was impossible to control.
Across the continent, countries like Spain, Portugal, and Switzerland have adopted more lenient approaches to cannabis. Spain allows private cannabis clubs to operate legally in a grey area, while Portugal’s 2001 decision to decriminalise all drugs has become a model for harm-reduction policies. Switzerland, though not part of the EU, has taken a pragmatic approach by launching cannabis pilot projects aimed at testing the effects of legalised sale and use.
The Economic Case for Legalisation
Behind the political and moral debates, there is a powerful economic argument for legalising cannabis. The cannabis industry represents a booming market, with estimates suggesting that legal cannabis in Europe could be worth over €3 billion by 2025. Legalisation presents a rare opportunity for governments to regulate and tax an industry that has long existed in the shadows.
In North America, where full cannabis legalisation has swept across many states and provinces, the economic benefits have been significant. Colorado, for instance, generated over $1.7 billion in cannabis sales in 2021 alone, contributing millions to public infrastructure projects, education, and healthcare. European governments are beginning to recognise that a legal and regulated cannabis market could boost public coffers while also addressing issues of safety and quality control in the currently unregulated black market.
The Challenges Ahead
Despite the momentum, the road to widespread legalisation across Europe is far from smooth. Cannabis remains illegal in most EU countries, and the regulatory frameworks for cannabis use are inconsistent at best. Many European nations remain cautious about opening the door to full legalisation, concerned about the social, legal, and health implications.
One of the most significant hurdles is the European Union’s legal framework, which places cannabis firmly under controlled substances. Any move toward legalisation must contend with international treaties and the EU’s own laws, which mandate member states to keep cannabis out of the hands of consumers. Even progressive countries like Luxembourg and Malta have faced pushback from the EU over their decisions to legalise.
There are also concerns about public health. Critics argue that legalisation could lead to increased consumption, particularly among younger populations, and raise questions about long-term health risks, particularly in mental health. Policymakers must balance the economic and social benefits of legalisation with the potential risks to public health and safety.
Trust and Provenance
The legalisation of cannabis in Europe is no longer a question of if, but when and how. Across the continent, a patchwork of laws, policies, and pilot projects is evolving, driven by a combination of public opinion, economic interest, and global trends. As more countries experiment with legalisation, Europe may well become the next frontier in the global cannabis movement. A key part of this movement will be trust in the actual product. By moving to fully legal adoption, governments, providers and consumers will want to enjoy the same protection as afforded any other products for human consumption. Therefore, trusted suppliers such as Dr Green in Portugal which use blockchain technology to provide full end to end provenance in the product – from plant to consumer – will be instrumental in delivering a quality product with known quantities and free from any unwanted additions or spoofing as it is termed in the current unregulated sector.